ProMIS Neurosciences Presents at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

Core Viewpoint - ProMIS Neurosciences Inc. is actively engaged in the development of therapeutic antibodies targeting toxic oligomers linked to neurodegenerative diseases, with a focus on Alzheimer's Disease, ALS, and MSA [1][3]. Company Overview - ProMIS Neurosciences is a clinical-stage biotechnology company based in Cambridge, Massachusetts, and Toronto, Ontario, specializing in the discovery and development of therapeutic antibodies for misfolded protein diseases [3]. - The company utilizes its proprietary target discovery engine, EpiSelect™, to identify Disease Specific Epitopes (DSEs) on misfolded proteins associated with various neurodegenerative diseases [3]. Product Development - PMN310 is the lead product candidate for Alzheimer's Disease, designed as a humanized monoclonal antibody that selectively targets toxic oligomers while avoiding plaque, potentially enhancing safety and efficacy compared to other therapies [4]. - The PRECISE-AD trial is a Phase 1b clinical study initiated to evaluate the safety, tolerability, and pharmacokinetics of PMN310 in patients with Mild Cognitive Impairment and mild Alzheimer's Disease [5]. - The trial aims to assess the effects of PMN310 on biomarkers related to Alzheimer's pathology and clinical outcomes, with a primary focus on safety and reduced risk of ARIA due to its non-plaque binding nature [5].